|
1
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
1:105–111. 2001. View
Article : Google Scholar
|
|
2
|
Charafe-Jauffret E, Monville F, Ginestier
C, Dontu G, Birnbaum D and Wicha MS: Cancer stem cells in breast:
current opinion and future challenges. Pathobiology. 75:75–84.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Phillips TM, McBride WH and Pajonk F: The
response of CD24(−/low)/CD44+ breast cancer-initiating
cells to radiation. J Natl Cancer Inst. 98:1777–1785. 2006.
|
|
4
|
Fillmore CM and Kuperwasser C: Human
breast cancer cell lines contain stem-like cells that self-renew,
give rise to phenotypically diverse progeny and survive
chemotherapy. Breast Cancer Res. 10:R252008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu R, Varghese S and Rabkin SD: Oncolytic
herpes simplex virus vector therapy of breast cancer in C3(1)/SV40
T-antigen transgenic mice. Cancer Res. 65:1532–1540. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang J, Hu P, Zeng M, Rabkin SD and Liu R:
Oncolytic herpes simplex virus treatment of metastatic breast
cancer. Int J Oncol. 40:757–763. 2012.PubMed/NCBI
|
|
7
|
Todo T, Martuza RL, Rabkin SD and Johnson
PA: Oncolytic herpes simplex virus vector with enhanced MHC class I
presentation and tumor cell killing. Proc Natl Acad Sci USA.
98:6396–6401. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ponti D, Costa A, Zaffaroni N, Pratesi G,
Petrangolini G, Coradini D, Pilotti S, Pierotti MA and Daidone MG:
Isolation and in vitro propagation of tumorigenic breast cancer
cells with stem/progenitor cell properties. Cancer Res.
65:5506–5511. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Neve RM, Chin K, Fridlyand J, Yeh J,
Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T,
Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL,
Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB,
Johnson MD, Lippman M, Ethier S, Gazdar A and Gray JW: A collection
of breast cancer cell lines for the study of functionally distinct
cancer subtypes. Cancer Cell. 10:515–527. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wakimoto H, Kesari S, Farrell CJ, Curry WT
Jr, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu
TC, Jeyaretna DS, Debasitis J, Pruszak J, Martuza RL and Rabkin SD:
Human glioblastoma-derived cancer stem cells: establishment of
invasive glioma models and treatment with oncolytic herpes simplex
virus vectors. Cancer Res. 69:3472–3481. 2009. View Article : Google Scholar
|
|
11
|
Hirsch HA, Iliopoulos D, Tsichlis PN and
Struhl K: Metformin selectively targets cancer stem cells, and acts
together with chemotherapy to block tumor growth and prolong
remission. Cancer Res. 69:7507–7511. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lim E and Winer EP: Adjuvant chemotherapy
in luminal breast cancers. Breast. (Suppl 3): 128–131. 2011.
View Article : Google Scholar
|
|
13
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
Baselga J and Norton L: Use of chemotherapy plus a monoclonal
antibody against HER2 for metastatic breast cancer that
overexpresses HER2. N Engl J Med. 344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Romond EH, Perez EA, Bryant J, Suman VJ,
Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman
PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG,
Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas
EP, Lingle WL, Klein PM, Ingle JN and Wolmark N: Trastuzumab plus
adjuvant chemotherapy for operable HER2-positive breast cancer. N
Engl J Med. 353:1673–1684. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Carey LA, Perou CM, Livasy CA, Dressler
LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S,
Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS
and Millikan RC: Race, breast cancer subtypes, and survival in the
Carolina Breast Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Banerjee S, Reis-Filho JS, Ashley S,
Steele D, Ashworth A, Lakhani SR and Smith IE: Basal-like breast
carcinomas: clinical outcome and response to chemotherapy. J Clin
Pathol. 59:729–735. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fulford LG, Reis-Filho JS, Ryder K, Jones
C, Gillett CE, Hanby A, Easton D and Lakhani SR: Basal-like grade
III invasive ductal carcinoma of the breast: patterns of metastasis
and long-term survival. Breast Cancer Res. 9:R42007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ginestier C, Hur MH, Charafe-Jauffret E,
Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS and Dontu G: ALDH1
is a marker of normal and malignant human mammary stem cells and a
predictor of poor clinical outcome. Cell Stem Cell. 1:555–567.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gonzalez-Angulo AM, Morales-Vasquez F and
Hortobagyi GN: Overview of resistance to systemic therapy in
patients with breast cancer. Adv Exp Med Biol. 608:1–22. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
O’Brien CS, Farnie G, Howell SJ and Clarke
RB: Breast cancer stem cells and their role in resistance to
endocrine therapy. Horm Cancer. 2:91–103. 2011.PubMed/NCBI
|
|
22
|
Ahtiainen L, Mirantes C, Jahkola T,
Escutenaire S, Diaconu I, Osterlund P, Kanerva A, Cerullo V and
Hemminki A: Defects in innate immunity render breast cancer
initiating cells permissive to oncolytic adenovirus. PLoS One.
5:e138592010. View Article : Google Scholar : PubMed/NCBI
|
